At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 111 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Double-Blind, Placebo-Controlled, 3-Month Trial of LY3298176 Versus Placebo in Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 2 clinical trial evaluating Tirzepatide and Placebo for Type 2 Diabetes. Completed, enrolled 111 participants across 13 sites.
Detailed Summary
The purpose of this study is to determine the efficacy of tirzepatide in participants with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedOct 2017
Enrollment StartOct 2017
Primary CompletionApr 2018
TodayJul 2026
First PostedOct 17, 2017
Enrollment StartOct 19, 2017
Primary CompletionApr 24, 2018
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.7 years ago
Interventions
Tirzepatidedrug
Administered SC
Placebodrug
Administered SC